Navigation Links
Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer
Date:7/14/2014

CAMBRIDGE, Mass., July 14, 2014 /PRNewswire/ -- Minerva Neurosciences (NASDAQ: NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that Frederick W. Ahlholm has been appointed vice president of finance and chief accounting officer, effective June 2, 2014. 

Mr. Ahlholm is a senior executive with more than 20 years of experience in directing the financial functions at technology and life science companies. His background includes the management of compliance and reporting requirements for companies registered with the U.S. Securities and Exchange Commission. Previously he was vice president of finance and chief accounting officer for Amarin Corporation plc, where he helped direct the growth of the company from a small clinical-stage drug developer into a commercial enterprise of more than 400 employees. He is a CPA and earned his BBA at the University of Notre Dame.

"I am excited to be joining Minerva Neurosciences at this pivotal time, and am looking forward to working with the rest of the executive team to advance our business strategy targeting a range of unmet needs and highly promising commercial opportunities in neuropsychiatric health in the years ahead," said Mr. Ahlholm.

The news of Mr. Ahlholm's appointment comes on the heels of the pricing of the company's initial public offering on June 30, 2014. Shares began trading on the NASDAQ Global Market under the ticker symbol "NERV" on July 1, 2014.

"Frederick's extensive experience with life sciences companies and his proven ability to contribute to the growth and success of clinical-stage organizations make him an ideal addition to the senior team at Minerva Neurosciences," said Rogerio Vivaldi, MD, MBA, Minerva president and CEO.

About Minerva
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neuropsychiatric diseases. The company was incorporated under the name Cyrenaic Pharmaceuticals, Inc. on April 23, 2007. In November 2013, it merged with Sonkei Pharmaceuticals, Inc. and the combined company was renamed Minerva Neurosciences, Inc. 

Media contact:
Jen Ringler
Berry & Company Public Relations
212.253.8881
jringler@berrypr.com

Investor contact:
Renee Leck
Stern Investor Relations
212.362.1200
renee@sternir.com


'/>"/>
SOURCE Minerva Neurosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Blanchette Rockefeller Neurosciences Institute Partners with Neurotrope BioScience to Advance New Alzheimers Disease Discoveries
2. Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference
3. Intellect Neurosciences Adds Two New Tau Programs to its Alzheimers Disease Development Pipeline
4. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
5. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
6. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
7. Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells
8. Ceres Announces Fiscal Third Quarter 2014 Financial Results
9. Pittcon Announces Second Year Partnership With Food Safety Tech
10. Organovo Announces Collaboration with National Institutes of Health
11. iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... and BEIJING , Nov. 30, 2016 ... provider of genomic services and solutions with cutting edge ... it has completed a USD $75 Million [515 Million ... Ltd.,s CMB International Capital Management ( Shenzhen ... Co., Ltd. ("SDIC Innovation") and Shanghai Sigma Square Investment ...
(Date:11/30/2016)... 30, 2016   Merck , a leading science ... into a set of agreements with Evotec AG, whereby ... of genetic reagents such as CRISPR and shRNA libraries. ... offers an accelerated pathway to explore and identify new ... identification of new targets, a process that can be ...
(Date:11/30/2016)... Park, NC (PRWEB) , ... November 30, 2016 ... ... company engaged in the development of a new orally administered treatment for Alzheimer’s ... and neuroimaging results of a Phase 2a clinical trial of T3D-959 in mild ...
(Date:11/30/2016)... Toronto, ON (PRWEB) , ... November 30, 2016 ... ... focused on discovery and development of precision treatments for neurodegenerative diseases, today announced ... disease (AD) (announced on November 3, 2016) blocked propagation of toxic, prion-like forms ...
Breaking Biology Technology:
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
(Date:11/17/2016)... 2016 Global Market Watch: Primarily supported ... Population-Based Banks and Academics) market is to witness a value ... shows the highest Compounded Annual Growth Rate (CAGR) of 10.75% ... the analysis period 2014-2020. North America ... by Europe at 9.56% respectively. ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory Inc ... and security for consumer electronics, and VeriTran ... and retail industry, today announced a global partnership ... way to authenticate users of mobile banking and ... TrulySecure™ software which requires no specialized biometric ...
Breaking Biology News(10 mins):